One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Neurocysticercosis as an Eradicable Cause of Epilepsy: A Plan and Actions Are Needed
Hector H. Garcia, MD, PhD1,2; Armando E. Gonzalez, DVM, PhD2,3; Robert H. Gilman, MD, DTMH4
doi : 10.1001/jamaneurol.2021.2349
JAMA Neurol. 2021;78(9):1045-1046
Respiratory Care for Patients With Amyotrophic Lateral Sclerosis in the US: In Need of Support
John Hansen-Flaschen, MD1
doi : 10.1001/jamaneurol.2021.2400
JAMA Neurol. 2021;78(9):1047-1048
Professional Soccer and Dementia Risk—The Ugly Side of the Beautiful Game
Breton M. Asken, PhD, ATC1,2; Gil D. Rabinovici, MD1,2,3,4,5
doi : 10.1001/jamaneurol.2021.2246
JAMA Neurol. 2021;78(9):1049-1051
Selection of Patients for Thrombectomy in the Extended Time Window
Jean-Claude Baron, MD, ScD1
doi : 10.1001/jamaneurol.2021.1825
JAMA Neurol. 2021;78(9):1051-1053
Poststroke Selective Serotonin Reuptake Inhibitors—Do They Work for Anything?
Michael D. Hill, MD, MSc1,2,3,4; Sean P. Dukelow, MD, PhD1,5
doi : 10.1001/jamaneurol.2021.1907
JAMA Neurol. 2021;78(9):1053-1054
Young-Onset Dementia—New Insights for an Underappreciated Problem
David S. Knopman, MD1
doi : 10.1001/jamaneurol.2021.1760
JAMA Neurol. 2021;78(9):1055-1056
Association of Field Position and Career Length With Risk of Neurodegenerative Disease in Male Former Professional Soccer Players
Emma R. Russell, MSc1; Daniel F. Mackay, PhD2; Katy Stewart, PhD3,4; John A. MacLean, MBChB3,4; Jill P. Pell, MD2; William Stewart, MBChB, PhD2,5
doi : 10.1001/jamaneurol.2021.2403
JAMA Neurol. 2021;78(9):1057-1063
Neurodegenerative disease mortality is higher among former professional soccer players than general population controls. However, the factors contributing to increased neurodegenerative disease mortality in this population remain uncertain.
Assessment of Optimal Patient Selection for Endovascular Thrombectomy Beyond 6 Hours After Symptom Onset: A Pooled Analysis of the AURORA Database
Gregory W. Albers, MD1,2; Maarten G. Lansberg, MD, PhD1,2; Scott Brown, PhD3; Ashutosh P. Jadhav, MD, PhD4; Diogo C. Haussen, MD5; Sheila O. Martins, MD, PhD6; Leticia C. Rebello, MD5; Andrew M. Demchuk, MD7,8; Mayank Goyal, MD, PhD7,8; Marc Ribo, MD9; Aquilla S. Turk, DO10; David S. Liebeskind, MD11,12; Jeremy J. Heit, MD, PhD13; Michael P. Marks, MD13; Tudor G. Jovin, MD14; Raul G. Nogueira, MD5; for the AURORA Investigators
doi : 10.1001/jamaneurol.2021.2319
JAMA Neurol. 2021;78(9):1064-1071
The optimal imaging approach for identifying patients who may benefit from endovascular thrombectomy (EVT) beyond 6 hours after they were last known well is unclear. Six randomized clinical trials (RCTs) have evaluated the efficacy of EVT vs standard medical care among patients with ischemic stroke.
Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial
Osvaldo P. Almeida, PhD1; Graeme J. Hankey, MD2; Andrew Ford, PhD1; Christopher Etherton-Beer, PhD2; Leon Flicker, PhD2; Maree Hackett, PhD3; for the Assessment of Fluoxetine in Stroke Recovery (AFFINITY) Trial Collaboration
doi : 10.1001/jamaneurol.2021.2418
JAMA Neurol. 2021;78(9):1072-1079
One in 3 adults experiences clinically significant symptoms of depression during the first year after a stroke, but evidence to support the use of antidepressants in this population remains scant.
Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis
Stevie Hendriks, MSc1; Kirsten Peetoom, PhD1; Christian Bakker, PhD2,3,4; Wiesje M. van der Flier, PhD5,6; Janne M. Papma, PhD7; Raymond Koopmans, PhD2,4; Frans R. J. Verhey, MD, PhD1; Marjolein de Vugt, PhD1; Sebastian Köhler, PhD1; and the Young-Onset Dementia Epidemiology Study Group
doi : 10.1001/jamaneurol.2021.2161
JAMA Neurol. 2021;78(9):1080-1090
Reliable prevalence estimates are lacking for young-onset dementia (YOD), in which symptoms of dementia start before the age of 65 years. Such estimates are needed for policy makers to organize appropriate health care.
Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial
Yongjun Wang, MD1,2; Yuesong Pan, PhD1,2; Hao Li, PhD1,2; Pierre Amarenco, MD3; Hans Denison, MD, PhD4; Scott R. Evans, PhD5; Anders Himmelmann, MD, PhD4; Stefan James, MD, PhD6; Filip Birve, BSc4; Per Ladenvall, MD, PhD4; Carlos A. Molina, MD, PhD7; S. Claiborne Johnston, MD, PhD8; for the THALES Steering Committee and Investigators
doi : 10.1001/jamaneurol.2021.2440
JAMA Neurol. 2021;78(9):1091-1098
Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These patients were included in the Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial, but results have not been reported separately, raising concerns about safety and efficacy in this subgroup.
Direct to Angiography Suite Without Stopping for Computed Tomography Imaging for Patients With Acute Stroke: A Randomized Clinical Trial
Manuel Requena, PhD1,2; Marta Olivé-Gadea, MD1,2; Marian Muchada, PhD1,2; David Hernández, MD3; Marta Rubiera, PhD1,2; Sandra Boned, PhD1,2; Carlos Piñana, MD3; Matías Deck, MD1,2; Álvaro García-Tornel, MD1,2; Humberto Díaz-Silva, MD3; Noelia Rodriguez-Villatoro, PhD1,2; Jesús Juega, MD1,2; David Rodriguez-Luna, PhD1,2; Jorge Pagola, PhD1,2; Carlos Molina, PhD1,2; Alejandro Tomasello, MD3; Marc Ribo, MD, PhD1,2
doi : 10.1001/jamaneurol.2021.2385
JAMA Neurol. 2021;78(9):1099-1107
Direct transfer to angiography suite (DTAS) for patients with suspected large vessel occlusion (LVO) stroke has been described as an effective and safe measure to reduce workflow time in endovascular treatment (EVT). However, it is unknown whether DTAS improves long-term functional outcomes.
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
Michelle M. Mielke, PhD1,2; Ryan D. Frank, MS1; Jeffrey L. Dage, PhD3; Andreas Jeromin, PhD4,5; Nicholas J. Ashton, PhD6,7,8,9,10; Kaj Blennow, MD, PhD6,10,11; Thomas K. Karikari, PhD6,10; Eugene Vanmechelen, PhD12; Henrik Zetterberg, MD, PhD6,10,11,13,14; Alicia Algeciras-Schimnich, PhD15; David S. Knopman, MD2; Val Lowe, MD16; Guojun Bu, PhD17; Prashanthi Vemuri, PhD16; Jonathan Graff-Radford, MD2; Clifford R. Jack Jr, MD16; Ronald C. Petersen, MD, PhD1,2
doi : 10.1001/jamaneurol.2021.2293
JAMA Neurol. 2021;78(9):1108-1117
Cerebrospinal fluid phosphorylated tau (p-tau) 181, p-tau217, and p-tau231 are associated with neuropathological outcomes, but a comparison of these p-tau isoforms in blood samples is needed.
Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis
Pavel Klein, MBBChir1; Orrin Devinsky, MD2; Jacqueline French, MD2; Cynthia Harden, MD3; Gregory L. Krauss, MD4; Robert McCarter, ScD5; Michael R. Sperling, MD6
doi : 10.1001/jamaneurol.2021.2480
JAMA Neurol. 2021;78(9):1118-1127
Most antiseizure medications (ASMs) carry a US Food and Drug Administration–mandated class label warning of increased suicidality risk, based on a meta-analysis comparing suicidality between individuals treated with medications vs placebo in randomized clinical trials done before 2008. ASMs approved since then carry this warning although they were not similarly studied.
Seizure Prophylaxis After Spontaneous Intracerebral Hemorrhage
Felipe J. S. Jones, MD1; Paula R. Sanches, MD1,2; Jason R. Smith, BA1,3; Sahar F. Zafar, MBBS1,4; Deborah Blacker, MD, ScD5,6,7; John Hsu, MD, MBA, MSCE8,9,10; Lee H. Schwamm, MD1,4; Joseph P. Newhouse, PhD8,11,12,13; Michael B. Westover, MD, PhD1,4; Lidia M. V. R. Moura, MD, MPH1,4
doi : 10.1001/jamaneurol.2021.2249
JAMA Neurol. 2021;78(9):1128-1136
Limited evidence is available concerning optimal seizure prophylaxis after spontaneous intracerebral hemorrhage (sICH).
Pathological Computed Tomography Features Associated With Adverse Outcomes After Mild Traumatic Brain Injury: A TRACK-TBI Study With External Validation in CENTER-TBI
Esther L. Yuh, MD, PhD1,2; Sonia Jain, PhD3; Xiaoying Sun, MS3; Dana Pisic?, MD4,15; Mark H. Harris, BS1,5; Sabrina R. Taylor, PhD1,5; Amy J. Markowitz, JD1,5; Pratik Mukherjee, MD, PhD1,2; Jan Verheyden, MS6; Joseph T. Giacino, PhD7,18; Harvey S. Levin, PhD8; Michael McCrea, PhD9; Murray B. Stein, MD, MPH10,11; Nancy R. Temkin, PhD12; Ramon Diaz-Arrastia, MD, PhD13; Claudia S. Robertson, MD14; Hester F. Lingsma, PhD15; David O. Okonkwo, MD, PhD16; Andrew I.R. Maas, MD, PhD17; Geoffrey T. Manley, MD, PhD1,5; and the TRACK-TBI Investigators for the CENTER-TBI Investigators
doi : 10.1001/jamaneurol.2021.2120
JAMA Neurol. 2021;78(9):1137-1148
A head computed tomography (CT) with positive results for acute intracranial hemorrhage is the gold-standard diagnostic biomarker for acute traumatic brain injury (TBI). In moderate to severe TBI (Glasgow Coma Scale [GCS] scores 3-12), some CT features have been shown to be associated with outcomes. In mild TBI (mTBI; GCS scores 13-15), distribution and co-occurrence of pathological CT features and their prognostic importance are not well understood.
Abnormal Movements in Bickerstaff Brainstem Encephalitis Mimicking Anti–N-Methyl-d-Aspartate Receptor Encephalitis
Masamune Kimura, MD1; Hajime Yoshimura, MD, PhD1; Nobuo Kohara, MD, PhD1
doi : 10.1001/jamaneurol.2021.1698
JAMA Neurol. 2021;78(9):1149
Mirrored-Self Misidentification in a Patient With Probable Alzheimer Dementia
Catarina Fernandes, MD1; Isabel Taveira, MD, MSc1; Hipólito Nzwalo, MD, MSc, PhD1,2
doi : 10.1001/jamaneurol.2021.2142
JAMA Neurol. 2021;78(9):1150
A 13-Year-Old Boy With Subacute-Onset Spastic Gait
Nina Xie, MD1,2; Jinxia Yang, BS1,2; Qiying Sun, MD, PhD1,2
doi : 10.1001/jamaneurol.2021.1953
JAMA Neurol. 2021;78(9):1151-1152
Adequate Initial Dosage and Tapering Methods of Steroids to Reduce the Total Corticosteroid Dose in Myasthenia Gravis
Hiroyuki Akamine, MD1; Akiyuki Uzawa, MD, PhD1; Satoshi Kuwabara, MD, PhD1
doi : 10.1001/jamaneurol.2021.2492
JAMA Neurol. 2021;78(9):1153
Adequate Initial Dosage and Tapering Methods of Steroids to Reduce the Total Corticosteroid Dose in Myasthenia Gravis—Reply
Simone Birnbaum, PhD1; Raphaël Porcher, PhD2; Tarek Sharshar, MD, PhD3
doi : 10.1001/jamaneurol.2021.2495
JAMA Neurol. 2021;78(9):1153-1154
